U.S. Food and Drug Administration Approves Pfizer`s XELJANZÂ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate